Skip to main content
. 2010 Dec;38(12):2166–2172. doi: 10.1124/dmd.110.035501

Fig. 2.

Fig. 2.

NOx production of primary human hepatocytes and its inhibition by proteasome inhibitors. Primary human hepatocytes were cultured for 3 days after delivery and treated with 1 mM PB for an additional 2 days. PB was maintained in the media during treatments. NOx was measured from media after treatment. A, hepatocytes (HH1390) were treated with ILmix (2.5 ng/ml IL-1β, 5 ng/ml TNF-α, and 5 ng/ml IFN-γ), the proteasome inhibitor MG132 (10 μM), or both for 18 h. B, hepatocytes (HH1402) were treated with ILmix, the proteasome inhibitor lactacystin (10 μM), or both or ILmix/lactacystin (10 μM) for 18 h. C, concentration dependence of the effects of proteasome inhibitors on NOx production. PB-treated hepatocytes (HH1395) were cotreated with ILmix and various concentrations of lactacystin (Lac) or epoxomicin (Epoxo) for 18 h, and NOx was measured in the media. Values are the mean ± S.D. of three independent samples. a, significantly different from control; b, significantly different from ILmix alone, P < 0.05.